CollPlant Biotechnologies Ltd. (CLGN) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 222.24
P/FCF
N/A
—
5yr avg: 182.46
30Y Low182.5·High182.5
P/B Ratio
↓
0.33
↓-94% vs avg
5yr avg: 5.88
30Y Low2.6·High16.6
ROE
↑
-79.5%
↑-42% vs avg
5yr avg: -56.0%
30Y Low-378%·High1%
Debt/EBITDA
N/A
—
5yr avg: 4.31
30Y Low4.3·High4.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CLGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CollPlant Biotechnologies Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $41M | $73M | $92M | $196M | $74M | $28M | $18M | — | — | — |
| Enterprise Value | $-4327522 | $32M | $49M | $65M | $186M | $74M | $28M | $13M | — | — | — |
| P/E Ratio → | -0.27 | — | — | — | 478.36 | — | — | — | — | — | — |
| P/S Ratio | 8.74 | 80.07 | 6.64 | 308.12 | 12.52 | 12.09 | 12.26 | 3.85 | — | — | — |
| P/B Ratio | 0.33 | 3.06 | 2.57 | 2.85 | 4.34 | 16.57 | 6.95 | 3.87 | — | — | — |
| P/FCF | — | — | — | — | 182.46 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 78.28 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CLGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 62.93 | 4.50 | 218.68 | 11.91 | 12.10 | 12.19 | 2.74 | — | — | — |
| EV / EBITDA | — | — | — | — | 222.24 | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 679.70 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 173.57 | — | — | — | — | — | — |
CLGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
CollPlant Biotechnologies Ltd. earns an operating margin of -3349.7%. Operating margins have expanded from -5718.1% to -3349.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -79.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -417.1% | -417.1% | 71.8% | -393.6% | 87.2% | 43.7% | 2.2% | 65.0% | 32.8% | -196.3% | — |
| Operating Margin | -3349.7% | -3349.7% | -68.5% | -5718.1% | 0.4% | -91.2% | -329.2% | -84.9% | -1244.2% | -9433.2% | — |
| Net Profit Margin | -3225.0% | -3225.0% | -64.0% | -5660.5% | 1.5% | -94.1% | -481.6% | -130.5% | -1209.6% | -9571.9% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -79.5% | -79.5% | -23.2% | -43.7% | 1.0% | -134.8% | -252.4% | -169.5% | -293.6% | -377.8% | -155.3% |
| ROA | -62.9% | -62.9% | -19.5% | -38.0% | 0.8% | -53.5% | -112.8% | -73.0% | -98.2% | -201.3% | -122.8% |
| ROIC | -273.5% | -273.5% | -108.7% | -62.4% | 0.2% | -99.4% | -337.5% | -1016.1% | -606.0% | -717.3% | -365.6% |
| ROCE | -74.0% | -74.0% | -22.9% | -41.3% | 0.2% | -75.9% | -108.2% | -60.4% | -138.3% | -319.1% | -156.0% |
CLGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $12M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 0.11 | 0.09 | 0.08 | 0.76 | 0.89 | 0.01 | 1.39 | — | — |
| Debt / EBITDA | — | — | — | — | 4.31 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.66 | -0.83 | -0.83 | -0.21 | 0.01 | -0.04 | -1.11 | -0.57 | -0.74 | -0.54 |
| Net Debt / EBITDA | — | — | — | — | -11.38 | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -8.89 | — | — | — | — | — | — |
| Interest Coverage | -1014.76 | -1014.76 | -751.20 | -502.85 | 1.76 | -164.68 | -104.53 | -156.37 | -56.52 | -450.65 | — |
Net cash position: cash ($12M) exceeds total debt ($3M)
CLGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
CollPlant Biotechnologies Ltd.'s current ratio of 4.44x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 10.20x to 4.44x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.44 | 4.44 | 8.62 | 10.20 | 14.96 | 1.68 | 1.46 | 3.19 | 4.56 | 1.19 | 2.28 |
| Quick Ratio | 4.29 | 4.29 | 8.40 | 9.74 | 14.60 | 1.30 | 1.20 | 2.83 | 4.42 | 1.11 | 2.28 |
| Cash Ratio | 4.01 | 4.01 | 8.20 | 9.55 | 14.37 | 0.98 | 1.10 | 2.38 | 3.62 | 0.56 | 1.42 |
| Asset Turnover | — | 0.03 | 0.32 | 0.01 | 0.31 | 0.57 | 0.22 | 0.53 | 0.06 | 0.02 | — |
| Inventory Turnover | 6.05 | 6.05 | 4.33 | 1.03 | 1.85 | 2.74 | 2.55 | 2.35 | 1.52 | 1.78 | — |
| Days Sales Outstanding | — | 413.19 | 13.09 | 10.99 | 6.30 | 49.36 | 12.44 | 39.33 | 77.59 | 4567.51 | — |
CLGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CollPlant Biotechnologies Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 0.2% | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 0.5% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $11M | $11M | $11M | $12M | $7M | $5M | $4M | $3M | $2M | $2M |
Peer Comparison
Compare CLGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CLGNYou | $5M | -0.3 | — | — | -417.1% | -3349.7% | -79.5% | -273.5% | — |
 RGEN | $7B | 147.0 | 52.4 | 75.9 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 ITGR | $3B | 30.4 | 13.1 | 28.8 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 OSUR | $225M | -3.3 | — | — | 41.9% | -59.2% | -18.3% | -20.0% | — |
 MGRX | $6M | -0.1 | — | — | 61.7% | -1294.4% | -118.3% | -83.8% | — |
 ANIK | $203M | -19.9 | — | 46.5 | 56.6% | -9.8% | -7.3% | -7.1% | — |
 MDXG | $548M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 TELA | $44M | -0.8 | — | — | 67.1% | -49.2% | -159.9% | -151.6% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See CLGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLGN vs RGEN
Side-by-side business, growth, and profitability comparison vs Repligen Corporation.
Start ComparisonCLGN — Frequently Asked Questions
Quick answers to the most common questions about buying CLGN stock.
What is CollPlant Biotechnologies Ltd.'s P/E ratio?
CollPlant Biotechnologies Ltd.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
What is CollPlant Biotechnologies Ltd.'s ROE?
CollPlant Biotechnologies Ltd.'s return on equity (ROE) is -79.5%. The historical average is -136.5%.
Is CLGN stock overvalued?
Based on historical data, CollPlant Biotechnologies Ltd. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are CollPlant Biotechnologies Ltd.'s profit margins?
CollPlant Biotechnologies Ltd. has -417.1% gross margin and -3349.7% operating margin.